Regcell raised $66 million in new financing and Japanese government support to bring its epigenetic Treg reprogramming platform toward the clinic. The funding supports clinical development of its Nobel-linked regulatory T-cell approach, designed to convert disease-driving immune cells into antigen-specific Tregs, as the company targets precision immune tolerance rather than broad immunosuppression.